mResvia

Respiratory syncytial virus mRNA vaccine (nucleoside modified) · Moderna Biotech Spain, S.L.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for mResvia, covering 2025-11-26 to 2026-08-27. Get the full timeline:

Most recent: EMA Authorised: mResvia (Single-stranded 5' capped mRNA encoding the respiratory syncytial virus glycoprotein F stabilised in the prefusion conformation) — Moderna Biotech Spain, S.L.

See pricing